期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

伊布利特对离子通道的作用及心电的影响特点 被引量：2

下载PDF
导出
摘要 伊布利特（Ibutilide）是一种新型Ⅲ类抗心律失常药物，其作用机制与其它的Ⅲ类抗心律失常药物不同，它不仅是β-肾上腺素受体拮抗剂的同系物，又是一种甲基磺胺类化合物。伊布利特对新发的心房扑动／心房颤动的治疗价值确切。循证医学证据证实，伊布利特能有效地转复心房扑动／心房颤动，
作者 昃峰 张海澄
机构地区 北京大学人民医院心脏中心
出处 《心电学杂志》 2010年第6期514-516,共3页 Journal of Electrocardiology(China)
关键词 伊布利特 离子通道 Ⅲ类抗心律失常药物 β-肾上腺素受体拮抗剂 心电 循证医学证据 心房颤动 心房扑动
分类号 R540.41 [医药卫生—心血管疾病] R541.7 [医药卫生—心血管疾病]
  • 相关文献

参考文献16

  • 1Fuster V,Ryden L E,Cannom D S,et al.ACC / AHA / ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation).Eur Heart J,2006,27:1979-2030.
  • 2Blomstrom-Lundqvist C,Scheinman M M,Aliot E M,et al.ACC/AHA / ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary.a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society.J Am Coll Cardiol,2003,42:1493-1531.
  • 3Lee K S,Gibson J K.Unique ionic mechanism of action of ibutilide on freshly isolated heart cells.Circulation,1995,92:2755-2757.
  • 4Lee K S,Lee E W.Ionic mechanism of ibutilide in human atrium:evidence for a drug-induced Na+ current through a nifedipine inhibited inward channel.J Pharmacol Exp Ther,1998,286:9-22.
  • 5Yang T,Snyders D J,Roden D M.Ibutilide,a methanesulfonanilide antiarrhythmic,is a potent blocker of the rapidly activating delayed rectifier K+ current (IK) in AT-1 cells.Concentration-,time-,voltage-,and use-dependent effects.Circulation,1995,91:1799-1806.
  • 6Sato N,Tanaka H,Habuchi Y,et al.Electrophysiological effects of ibutilide on the delayed rectifier K(+) current in rabbit sinoatrial and atrioventricular node cells.Eur J Pharmacol,2000,404:281-288.
  • 7Baskin E P,Lynch J J.Differential atrial versus ventricular activities of class Ⅲ potassium channel blockers.J Pharmacol Exp Ther,1998,285:135-142.
  • 8Glatter K A,Dorostkar P C,Yang Y,et al.Electrophysiological effects of ibutilide in patients with accessory pathways.Circulation,2001,104:1933-1939.
  • 9Chen Y J,Hsieh M H,Chiou C W,et al.Electropharmacologic characteristics of ventricular proarrhythmia induced by ibutilide.J Cardiovasc Pharmacol,1999,34:237-247.
  • 10Wood M A,Stambler B S,Ellenbogen K A,et al.Suppression of inducible ventricular tachycardia by ibutilide in patients with coronary artery disease.Ibutilide Investigators.Am Heart J,1998,135:1048-1054.

同被引文献28

  • 1Panagiotis Korantzopoulos,Konstantinos P Letsas,Anna Kotsia,Giannis Baltogiannis,Kallirroi Kalantzi,Konstantinos Kyrlas,John A Goudevenos.Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients[J].World Journal of Cardiology,2013,5(7):242-246. 被引量：3
  • 2中华医学会心血管病学分会心律失常学组,中华心血管病杂志编辑委员会,中国心脏起搏与心电生理杂志编辑委员会.获得性长QT间期综合征的防治建议[J].中国心脏起搏与心电生理杂志,2010,24:471-479.
  • 3Zareba W. Drug induced QT prolongation lJ]. CardiolJ, 2007, 14 (6): 523-533.
  • 4Zipes DP, Camm AJ, Borggrefe M, et ai. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force and the European society of cardiology committee for practice guidelinJ J]. Europace, 2006, 8 (9): 746-837.
  • 5Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone[J] . Ann Intern Med, 2002, 137 (6): 501-504.
  • 6Hennessy S, Bilker WB, KnaussJS, et al. Cardiac arrest and ventricular arrhythmia in pat ients taking antipsychotic drugs: cohort study using administrative data] J]. BMJ, 2002, 325 (7372): 1070.
  • 7WiltJL, Minnema AM,Johnson RF, et al. Torsade de pointes associated with the use of in travenous haloperidol[J] . Ann Intern Med, 1993, 119 (5): 391-394.
  • 8Lehtonen A, Fodstad H, Laitinen-Forsblom P, et ai. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes[J]. Heart Rhythm, 2007, 4 (5) : 603-607.
  • 9Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes[J] . N EnglJ Med, 2004, 351 (11): 1089-1096.
  • 10Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and moxifloxacin] J]. Pharmacotherapy, 2001, 21 (12): 468-472.

引证文献2

二级引证文献14

心电学杂志
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部